Fazili, TasaduqBansal, Ekta N.Garner, DorothyGomez, MarianaStornelli, Nicholas2023-02-092023-02-092023-020924-8579http://hdl.handle.net/10919/113754Dalbavancin is a parenteral lipoglycopeptide antibiotic derived from teicoplanin, an analog of vancomycin. It is mainly used for skin and soft tissue infections. The sustained half-life of around 14 days makes dalbavancin a novel option for potential use as sequential treatment in infections like infective endocarditis, which require prolonged antibiotic courses. However, only a few studies have been reported in the literature and its use remains limited. We reviewed the currently available literature using dalbavancin in the treatment of infective endocarditis due to Gram-positive organisms. Almost all patients received dalbavancin as sequential therapy following standard of care antibiotics. The overall clinical efficacy was around 90% and it appeared to be well tolerated.application/pdfenIn CopyrightArticle - Refereed2023-02-09https://doi.org/10.1016/j.ijantimicag.2023.106749Gomez, Mariana [0000-0001-8963-9959]